- Nachrichtendetail
-
13.05.2024 07:39:16 - dpa-AFX: *REGENERON: FDA ACCEPTS FOR PRIORITY REVIEW SBLA FOR DUPIXENT FOR CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS
Copyright(c) 2024 RTTNews.com. All Rights Reserved
Copyright RTT News/dpa-AFX
Copyright RTT News/dpa-AFX
| Name | WKN | Börse | Kurs | Datum/Zeit | Diff. | Diff. % | Geld | Brief | Erster | Schluss | |
|---|---|---|---|---|---|---|---|---|---|---|---|
 |
SANOFI SA INHABER EO 2 | 920657 | Frankfurt | 90,130 | 10.06.24 21:26:01 | -0,330 | -0,36% | 0,000 | 0,000 | 90,820 | 90,460 |
|
REGENERON PHARMAC.DL-,001 | 881535 | Frankfurt | 924,800 | 10.06.24 15:49:15 | +10,400 | +1,14% | 0,000 | 0,000 | 928,000 | 914,400 |
